With Biotech (XBI) down 2.0%, this looks like a sector-led move rather than a company-specific surprise.
The biotech sector, as measured by the XBI ETF, fell today primarily due to negative sentiment following the FDA's decision to not approve Summit Therapeutics' lung cancer drug, ivonescimab. The agency is requiring further data showing a significant improvement in overall survival. This news overshadowed positive clinical trial results from some other biotech companies and was exacerbated by a broader market downturn, particularly in the technology sector, creating a "risk-off" environment for growth-oriented industries like biotechnology.